1/130
Looks like no tags are added yet.
Nonselective alpha-1 blockers (generic/trade)
Doxazosin (Cardura); prazosin (Minipress); terazosin (Hytrin)
Selective alpha-1 blockers (generic/trade)
Alfuzosin (Uroxatral); tamsulosin (Flomax)
Doxazosin (Cardura) dose
PO; 1-8 mg daily
Prazosin (Minipress) dose
PO; 0.5-1 mg twice daily
Terazosin (Hytrin) dose
PO; 1-20 mg at night
Alfuzosin (Uroxatral) dose
PO; 10 mg daily
Tamsulosin (Flomax) dose
PO; 0.4 mg daily
Alpha-1 blockers: mechanism of action
Block alpha-adrenergic stimulation → relax prostatic smooth muscle
Alpha-1 blockers: onset of symptom relief
Almost immediate
Alpha-1 blockers: time to max effect
Several days to a couple of weeks
Alpha-1 blockers: after stopping the drug
Effect reverses soon after discontinuation
Alpha-1 blockers: absorption
Well absorbed orally; tamsulosin absorbed slowly
Alpha-1 blockers: distribution
Widely distributed throughout the body
Alpha-1 blockers: metabolism
Extensively metabolized in the liver
Alpha-1 blockers: excretion
Feces and urine
Alpha-1 blockers used for BPH
All: doxazosin, prazosin, terazosin, tamsulosin, alfuzosin
Alpha-1 blockers also used for hypertension
Doxazosin, prazosin, terazosin
Alpha-1 blocker used for nightmares
Prazosin
Alpha-1 blockers: CV adverse reaction
Orthostatic hypotension
Alpha-1 blockers: EENT adverse reaction
Rhinitis
Alpha-1 blockers: endocrine adverse reactions
Decreased libido; ejaculation failure
Alpha-1 blockers: GI adverse reactions
Diarrhea; nausea; stomach discomfort
Alpha-1 blockers: MSK adverse reactions
Muscle pain; back pain
Alpha-1 blockers: neuro adverse reactions
Headache; dizziness; fatigue
Alpha-1 blockers: interactions
Any BP-lowering drug, including PDE5 inhibitors and all antihypertensives
Alpha-1 blockers: contraindications
Hypersensitivity; concurrent use with any PDE5 inhibitor
Alpha-1 blockers: when to give the first dose
In clinic or at bedtime (first-dose reaction risk)
Alpha-1 blockers: how to minimize first-dose orthostatic hypotension
Start low; increase dose at 2-week intervals
Alpha-1 blockers: patient education - orthostasis
Caution about orthostatic hypotension, especially getting out of bed at night
Alpha-1 blockers: patient education - side effects over time
Often fade with continued use; may return if therapy is stopped and restarted
5-alpha reductase inhibitors (generic/trade)
Dutasteride (Avodart); finasteride (Proscar)
Dutasteride (Avodart) dose
Oral; 0.5 mg daily
Finasteride (Proscar) dose for BPH
Oral; 5 mg daily for a minimum of 6 months
Hormone that stimulates prostate growth
Dihydrotestosterone (DHT)
5-ARIs: mechanism of action
Competitively inhibit type 2 5-alpha reductase → blocks testosterone → DHT conversion in prostate
Blocking DHT decreases which 2 conditions?
Benign prostatic hyperplasia; androgenetic alopecia
5-ARIs: absorption
Well absorbed
5-ARIs: distribution
Widely distributed; 90% protein-bound
5-ARIs: metabolism
Mainly liver (40-50%) to active metabolites
5-ARIs: excretion
More than half in feces; rest in urine
5-ARIs: clinical uses
BPH; male pattern baldness; PCOS; prostate cancer; male-to-female transgender hormone therapy
5-ARIs: derm adverse reaction
Cutaneous hypersensitivity
5-ARIs: endocrine adverse reactions
Impotence/ED; decreased libido; gynecomastia
5-ARIs: GU adverse reaction / lab effect
Decreased PSA, even if prostate cancer is present
5-ARIs: interactions
CYP3A4 inhibitors (ketoconazole) or inducers (St. John's wort)
5-ARIs: contraindications
Hypersensitivity; serious skin reaction to another 5-ARI; pediatric patients; pregnancy
Finasteride: teratogenic effect
Abnormal genitalia in male offspring
Finasteride: handling precaution
Should not be handled by women who are or may become pregnant
5-ARIs: blood donation
Avoid donating blood for at least 6 months after the drug
5-ARIs: combination therapy trend
Combined with an alpha blocker is becoming more common
5-ARIs: effect of daily treatment
Lower serum DHT → suppress prostate growth, decrease volume up to 30%, increase urine flow
5-ARIs: max decrease in prostate volume
Up to 30%
Why is the 5-ARI PSA drop a concern?
PSA is used to screen for prostate cancer
5-ARIs: patient education - time to relief
3-6 months of therapy may be needed
Testosterone deficiency: definition
Endocrine deficiency state with decreased testosterone levels
Hypogonadism: definition
Low serum testosterone with associated symptoms
Hypogonadism: mood/energy/cognition symptoms
Depressed mood; diminished energy; fatigue; impaired cognition
Hypogonadism: body composition symptoms
Decreased muscle strength and bulk; increased fat mass; decreased bone density
Hypogonadism: metabolic/blood findings
Anemia; increased insulin resistance
Hypogonadism: sexual symptoms
Decreased libido; ED
Total testosterone measures
Free + bound testosterone
Primary vs. secondary testosterone deficiency
Primary = gonadal/testicular failure; secondary = hypothalamic-pituitary failure
Testosterone deficiency: labs to order
Total testosterone; free testosterone; SHBG-bound testosterone; LH; FSH
Low testosterone + low or normal LH/FSH suggests
Hypothalamic-pituitary problem; further workup (MRI)
Testosterone deficiency: why order CBC and fasting glucose?
Deficiency can cause anemia and insulin resistance
Testosterone deficiency: treatment
Exogenous testosterone
Methyltestosterone (Android)
PO; 10-50 mg daily
Fluoxymesterone (Halotestin)
PO; 5-20 mg daily
Testosterone buccal (Striant)
Buccal; 30 mg 2 times/day
Testosterone patch (Androderm)
Nonscrotal skin; 2.5-5 mg/24 hr daily
Testosterone cypionate (Depo-Testosterone)
IM; 50-400 mg every 2-4 weeks
Testosterone enanthate (Delatestryl)
IM; 50-400 mg every 2-4 weeks
Testosterone 1% gel (AndroGel)
Nonscrotal skin; 5 g daily
Testosterone pellets (Testopel)
SC; 150-450 mg every 3-6 months
Exogenous testosterone: pharmacokinetics vary by
Ester type and route of administration
Testosterone: absorption
Complete when given IM
Testosterone: distribution
~98% protein-bound to sex hormone-binding globulin (SHBG)
Testosterone: metabolism
First-pass hepatic metabolism; active metabolites
Testosterone: excretion
90% urine; rest feces
Testosterone: clinical uses
Delayed male puberty; male hypogonadism (replacement); male osteoporosis
Testosterone: CV adverse reactions
MI; CVA; DVT/PE
Testosterone: derm adverse reactions
Acne; hirsutism; male pattern baldness
Testosterone: endocrine adverse reactions
Breast soreness; gynecomastia
Testosterone: GI adverse reaction
Nausea
Testosterone: GU adverse reactions
Priapism; testicular atrophy; oligozoospermia
Testosterone: heme/hepatic adverse reactions
erythrocytosis; polycythemia
Testosterone: neuro adverse reactions
Aggression; amnesia; anxiety; depression; nervousness; sleeplessness
Testosterone: drug interaction
Oral anticoagulants (warfarin): increased anticoagulant (hypothrombotic) effect
Testosterone: contraindications
Hypersensitivity; male breast cancer; prostate cancer; pregnancy
Testosterone: H&P monitoring schedule
Every 3-4 months for 1 year, then annually
Testosterone: poor or no response at 3-4 months
Increase dose, or stop if at maximum dose
Testosterone: lab monitoring
Lipids; PSA; hematocrit
IM testosterone: when to draw levels
Just before the next IM dose, until stable
Oral testosterone: extra monitoring
LFTs every 3-6 months
Testosterone: cancer concern
Suspected stimulant of breast and prostate cancer; keep up screening
Testosterone: who needs erythropoiesis monitoring?
Smokers; vascular disease; history of polycythemia
Testosterone: significant hematocrit rise
Discontinue medication
Testosterone: controlled substance schedule
Schedule III (all forms)
Testosterone: patient education - expected results
Many symptoms don't respond; age and physical condition may limit results
Testosterone: patient education - pregnant women
Pregnant or childbearing-age women should avoid contact with gels/patches; fetal harm possible